Fig.1 OXA induced AD model in hIL4/hIL4R mice. (A) body weight (B) body weight change.
Fig.2 OXA induced AD model in hIL4/hIL4R mice. (A) gross observation on Day 21 (B) ear thickness (C) clinical score of skin.
Fig.3 OXA induced AD model in hIL4/hIL4R mice. (A) serum IgE (B) spleen weight.
Fig.4 OXA induced AD model in hIL4/hIL4R mice. (A) Pathology photos (B) Pathology score.
Fig.1 Body weight of hIL4/hIL4Ra mice treated with dupilumab. *P<0.05.
Fig.2 Dupilumab ameliorate overall atopic dermatitis activity in DNFB-induced AD Model. *P<0.05, **P<0.01, ***P<0.001.
Fig.3 Dupilumab treatment significantly reduced IgE levels in serum and scratching times. (A) day10 serum IgE (B) day16 serum IgE (C) scratch times on Day 12 (D) scratch times on Day 14. *P<0.05, **P<0.01, ***P<0.001.
Fig.4 Dupilumab significantly mitigates inflammatory cell infiltration in lesioned skin on day 14. (A) dorsal image on day14; (B) Representative pathology images; (C) Inflammatory cell infiltration score; (D) neutrophils score; (E) eosinophils score; (F) epidermis thickness; (G) dermis thickness. *P<0.05, **P<0.01, ***P<0.001.
请完整填写订购意向单,我们会在2个工作日内与您联系。